Microenvironment targets in KRAS-mutated metastatic colorectal cancer

被引：0
|
作者：
Marchio, Serena [1 ]
Bartolini, Alice [1 ]
Cardaci, Sabrina [2 ]
Soster, Marco [2 ]
Corti, Giorgio [1 ]
Lamba, Simona [1 ]
Bussolino, Federico [2 ]
Cora', Davide [1 ]
Nicolantonio, Federica D. [2 ]
机构：
[1] Inst Canc Res & Treatment, Candiolo, Italy
[2] Univ Turin, Candiolo, Italy
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1163
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [22] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [23] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
  • [24] Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
    Bellier, Justine
    Nokin, Marie-Julie
    Caprasse, Maurine
    Tiamiou, Assia
    Blomme, Arnaud
    Scheijen, Jean L.
    Koopmansch, Benjamin
    MacKay, Gillian M.
    Chiavarina, Barbara
    Costanza, Brunella
    Rademaker, Gilles
    Durieux, Florence
    Agirman, Ferman
    Maloujahmoum, Naima
    Cusumano, Pino G.
    Lovinfosse, Pierre
    Leung, Hing Y.
    Lambert, Frederic
    Bours, Vincent
    Schalkwijk, Casper G.
    Hustinx, Roland
    Peulen, Olivier
    Castronovo, Vincent
    Bellahcene, Akeila
    CELL REPORTS, 2020, 30 (05): : 1400 - +
  • [25] Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer
    Goel, Sanjay
    Ocean, Allyson J.
    Parakrama, Ruwan Y.
    Ghalib, Mohammad H.
    Chaudhary, Imran
    Shah, Umang
    Viswanathan, Sengottuvel
    Kharkwal, Himanshu
    Coffey, Matthew
    Maitra, Radhashree
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1148 - 1156
  • [26] PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer
    Harvey, Harry
    Chen, Eric Xueyu
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1987 - 1992
  • [27] Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
    Lavacchi, Daniele
    Gelmini, Stefania
    Calabri, Adele
    Rossi, Gemma
    Simi, Lisa
    Caliman, Enrico
    Mancini, Irene
    Salvianti, Francesca
    Petroni, Giulia
    Guidolin, Alessia
    Scolari, Federico
    Messerini, Luca
    Pillozzi, Serena
    Pinzani, Pamela
    Antonuzzo, Lorenzo
    HELIYON, 2023, 9 (11)
  • [28] Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation
    Morris, Van Karlyle
    Overman, Michael J.
    Eng, Cathy
    Sanchez, Eduardo Vilar
    Morelli, Maria
    Jiang, Zhiqin
    Luthra, Rajyalakshmi
    Maru, Dipen M.
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Serova, Maria
    Riveiro, Maria Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [30] Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases
    Shindoh, Junichi
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (05)
12345